Loading…
← CockpitCompetitor Analysis › 214150.KS CLASSYS Inc.Open in the cockpit ↗

CLASSYS Inc.214150.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Medical Specialties

Korean maker of aesthetic medical devices (HIFU/RF skin-tightening systems) sold to dermatology and plastic-surgery clinics worldwide.

Momentum laggard 10
Mkt cap
$1.08B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$4.41M
20-day average traded
Fwd P/E
13.7×
forward earnings
ROIC−WACC
+13.9 pp
WACC 5.9%
Hurdle
-44 pp
Req g minus delivered
Next earnings
92 days
18 Feb 2027
Close · KRW₩22,200
1D-1.1%
1W-11.9%
1M-25.4%
3M-40.8%
6M-59.6%
YTD-59.3%
1Y-53.7%
ATR %7.2%
52w lowhigh71.4% off high

What CLASSYS does

Korean maker of aesthetic medical devices (HIFU/RF skin-tightening systems) sold to dermatology and plastic-surgery clinics worldwide.

Sells its machines to clinics largely through distributors, and earns repeat income from the single-use cartridges each treatment uses up, so a machine already installed keeps generating orders. Exports are a large part of sales.

Products and services

  • Shurink (HIFU device)
  • RF-based devices
  • Consumables/cartridges

Customers

  • Dermatology and plastic-surgery clinics (Korea, gl

Where it sits in the supply chain

  • Medical devices
  • Aesthetic energy-based devices
  • Dermatology/plastic-surgery clinic…

What could go right

  • Global aesthetic-device export growth

What could go wrong

  • Regulatory clearance risk in new markets
  • Device price competition

Moat: narrow (IP / patents, regulatory licence). Patented energy-based device technology plus regulatory clearances across many export markets.

Headquarters: Seoul, South Korea · Founded: 2007 · Employees: 528

Named competitors

  • Hugel 145020.KS
  • Lutronic 328130.KS
  • Merz Aesthetics private or unlisted

CLASSYS at a glance

Size CLASSYS (214150.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $1.08B, the 229th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩22,200 on 18 Nov 2026.

Performance Over six months the shares fell 59.6%, against -4.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.

Growth Revenue grew 16.2% over the last twelve months (peer median +8.3%); the operating margin is 43.2% (peer median 11.6%).

Valuation It trades at 13.7× forward earnings against a peer median of 18.5× (3rd cheapest of 12).

Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -44 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.9 points above its cost of capital (5.9% WACC).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 95214150.KS 44
Six months, rebased to 100: CLASSYS against the median of its 20 peers (local-currency closes).

CLASSYS financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩369B₩337B₩243B₩180B₩142B
Revenue growth—+39%+35%+27%—
Gross profit₩263B₩250B₩187B₩139B₩107B
EBITDA₩175B₩185B₩130B₩93.9B₩72.3B
Net income₩111B₩132B₩97.9B₩74.2B₩75.4B
Free cash flow₩39.3B₩101B₩98.7B₩60.2B₩27.3B
Capital expenditure₩36.4B₩19.3B₩10.8B₩6.11B₩28.0B
Total debt₩141B₩86.8B₩91.1B₩65.6B₩67.9B

Quarterly statements and history in the cockpit →

CLASSYS competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%IART301101ATEC688622SIBNIRMDDRTS300406CSTLEUZ6000553010216523688161300685300206CBLL300143TNDM214150.KS6-month return →1-month return →
Up and to the right = strong over both horizons. CLASSYS is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×IART301101ATECIRMD300406EUZ6523688161300685300206300143214150.KSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CLASSYS is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%IART301101IRMD300406CSTL3010216523688161300206300143214150.KSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. CLASSYS is the large dot.

CLASSYS competitors and peer comparison

Head to head with its named competitors (214150.KS vs 145020.KS vs 328130.KS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CLASSYS 214150.KS$1.08B-60%+16%43%13.7×-9.2%
Hugel 145020.KS$1.69B-30%+17%38%18.1×-12.1%
Lunit 328130.KS$883M-15%+23%-63%n/an/a

How CLASSYS compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CLASSYS against its 20 peers (data as of 18 Nov 2026)
Measure214150.KSPeer medianRank in peer set
1-month return-25.4%-5.1%3rd lowest of 21
6-month return-59.6%-4.5%lowest of 20
Distance from 52-week high-71.4%-29.4%lowest of 21
Revenue growth (TTM)+16.2%+8.3%4th highest of 19
Operating margin43.2%11.6%highest of 20
Forward P/E13.7×18.5×3rd cheapest of 12
Growth the price implies (Req g, 7 yrs)-9.2%8.2%least demanding of 13
Growth delivered (Del g)+34.5%+9.3%2nd highest of 13
Hurdle (Req g minus delivered)-43.7 pp-1.1 ppleast demanding of 13
ROIC minus cost of capital+13.9 pp+0.3 pp6th highest of 19
EV / EBITDA8.4×10.3×3rd cheapest of 7
Net debt / EBITDA0.2×1.2×4th least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%19.3×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%18.0×6.9%-2.9%
Ceribell CBLLUnited States$995M+42%+31%-70%n/an/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%50.3×10.7%+12.9%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a

Questions

Who are CLASSYS's main competitors?
Named competitors: Hugel (145020.KS), Lutronic (328130.KS), Merz Aesthetics (private or unlisted). The cockpit's measured peer set (industry) also includes Integra LifeSciences (IART), Freenome (FRNM), Mingyue Optical Lens (301101.SZ), Alphatec (ATEC), Guangzhou Hexin Instrument (688622.SS), SI-BONE (SIBN).
Is CLASSYS expensive compared with its peers?
On forward p/e it trades at 13.7× against a peer median of 18.5×, 3rd cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -44 pp: the price already allows for a slowdown.
How has CLASSYS stock performed?
Over six months to 18 Nov 2026 the shares returned -59.6% against -4.5% for the median peer; over one year -53.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.